Canadian, Asian alternatives fundraises among $390m of new LACERA commitments altassets.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from altassets.net Daily Mail and Mail on Sunday newspapers.
Lilly Asia Ventures leads $90m Series B in clinical-stage biotech firm Regor
February 19, 2021
Regor Therapeutics, a clinical-stage biotech company with operations in China and the US, has secured $90 million in a Series B round of financing led by the biomedical venture capital (VC) firm Lilly Asia Ventures (LAV).
The new round saw participation from investors including China-focused private equity (PE) firm Loyal Valley Capital (LVC); cross-border, pharmaceutical-focused PE Lanting Capital (LVC); TF Capital, which primarily invests in early-stage life sciences startups; and Vertex Ventures China.
Chinese drug maker Qilu Pharmaceutical Group had backed Regor’s Series A round.
Founded in July 2018, Regor specialises in the discovery and delivery of clinically differentiated, best- and first-in-class drugs for patients globally to treat cancer, immune disorders, and metabolic diseases.
Los Angeles County Employees allocates $390 million to 5 funds
Print
Los Angeles County Employees Retirement Association, Pasadena, Calif., committed a total of $390 million to five alternative investment funds, according to an executive session report on the $65.4 billion pension fund s website.
LACERA s board of investment at its Jan. 13 meeting approved commitments of up to $100 million total to venture capital funds LAV Fund VI and LAV Fund VI Opportunities, both managed by
Lilly Asia Ventures.
The board also approved commitments of up to $100 million each to Grain Communications Opportunity Fund III, a telecommunications infrastructure fund managed by
Grain Management; and buyout fund
Novacap TMT VI; and up to €75 million ($90 million) to
San Francisco Employees allocates $148 million to 3 alts funds
Print
San Francisco City & County Employees Retirement System disclosed commitments and investments totaling $148 million in a report from CIO William J. Coaker Jr. ahead of its Feb. 10 board meeting.
The $30.7 billion pension fund made a direct hedge fund investment of $100 million in
RTW Innovation Fund, an opportunistic fund that invests in health-care companies managed by RTW Investments.
It is SFERS first investment with RTW and is classified as an opportunistic investment within the pension fund s public equities portfolio.
As of Jan. 31, the actual allocation to public equities was 39.4%.
Also, SFERS committed $32 million to multistage venture capital fund LAV Fund VI and $16 million to late-stage venture capital fund LAV Fund VI Opportunities, both managed by